°ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå ±Ô¸ð, Á¡À¯À², ºÐ¼® º¸°í¼­ : À¯Çüº°, Á¦Ç°º°, À¯Åë ä³Îº°, Áö¿ªº°, ºÎ¹®º° ¿¹Ãø(2025-2030³â)
Irritable Bowel Syndrome Treatment Market Size, Share & Analysis Report By Type (IBS-C, IBS-D), By Product (Xifaxan, Linzess/Constella, Viberzi, Amitiza), By Distribution Channel, By Region, And Segment Forecasts, 2025 - 2030
»óǰÄÚµå : 1587544
¸®¼­Ä¡»ç : Grand View Research, Inc.
¹ßÇàÀÏ : 2024³â 10¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 100 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,950 £Ü 8,443,000
Unprintable PDF & Excel (Single User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» 1Àθ¸ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â ºÒ°¡´ÉÇÕ´Ï´Ù.
US $ 6,950 £Ü 9,862,000
Printable PDF & Excel (5-User License) help
º¸°í¼­ PDF ¹× ¿¢¼¿À» µ¿ÀÏ ±â¾÷ ³» µ¿ÀÏ ºÎ¼­¿¡¼­ ÃÖ´ë 5¸í±îÁö »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, Àμâ´Â °¡´ÉÇÕ´Ï´Ù.
US $ 8,950 £Ü 12,700,000
Printable PDF & Excel (Enterprise License) help
º¸°í¼­ ±¸¸Å ±â¾÷ ¹× ±× ÀÚȸ»ç, °ü°è»ç°¡ »ç¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀ̸ç, PDF ¹× ¿¢¼¿ ÅØ½ºÆ® µîÀÇ º¹»ç ¹× ºÙ¿©³Ö±â, ÀμⰡ °¡´ÉÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

°ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå ¼ºÀå ¹× µ¿Çâ:

Grand View Research, Inc.ÀÇ ÃֽŠº¸°í¼­¿¡ µû¸£¸é °ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ¼¼°è ½ÃÀå ±Ô¸ð´Â 2025³âºÎÅÍ 2030³â±îÁö ¿¬Æò±Õ 8.8% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 60¾ï 2,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

´ë»ó ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ±âÁ¸ ¾à¹°ÀÇ ÀûÀÀÁõ È®´ë°¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÈ­ÇÒ °¡´É¼ºÀÌ ³ô½À´Ï´Ù. ¶ÇÇÑ, ¾à¹°ÀÇ º¸±Þ°ú ½ÅÁ¦Ç° Ãâ½Ã°¡ °ú¹Î¼º´ëÀåÁõÈıº(IBS) Ä¡·áÁ¦ ½ÃÀåÀ» °ßÀÎÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

IBS´Â °¡Àå ÈçÇÑ À§À庴 Áß ÇϳªÀ̸ç, Àü ¼¼°è À¯º´·üÀº º¸Åë 10-15%ÀÔ´Ï´Ù. IBS ȯÀÚÀÇ ´ëºÎºÐÀº 50¼¼ ¹Ì¸¸ÀÌÁö¸¸, ³ëÀε鵵 ¸¹ÀÌ ¾Î°í ÀÖ½À´Ï´Ù. Áõ»óÀÇ ¿µÇâÀº °æ¹ÌÇÑ ºÒÆíÇÔ¿¡¼­ ½É°¢ÇÑ ¼è¾à¿¡ À̸£±â±îÁö ´Ù¾çÇϸç, IBS´Â ȯÀÚÀÇ ¾÷¹«, °¨Á¤ ¹× »çȸ »ýȰÀÇ ´Ù¾çÇÑ Ãø¸éÀ» Áö¹è ÇÒ ¼ö ÀÖ½À´Ï´Ù. Áߵ¿¡¼­ ÁßÁõÀÇ È¯ÀÚ´Â ÀϹÝÀûÀ¸·Î Á¤¼­Àû, ½ÅüÀû, ±³À°Àû, »çȸÀû, °æÁ¦Àû ¾È³çÀ» ÀÚÁÖ ¼Õ»ó½ÃŰ´Â Áõ»ó°ú ½Î¿ì°í ÀÖ½À´Ï´Ù.

Áõ»óÀº ´Ù¾çÇÏ¸ç ¶§·Î´Â º¯ºñ¿Í ¼³»ç°¡ ¹ø°¥¾Æ °¡¸ç ¶§·Î´Â ¸ð¼øµÇ±âµµ ÇÕ´Ï´Ù. Àå±âÀûÀÎ Áõ»óÀº ȯÀÚÀÇ ¾÷¹« ¹× °³ÀΠȰµ¿À» ¹æÇØÇϰí ÀϹÝÀûÀ¸·Î °³ÀÎÀÇ ÀáÀç·ÂÀ» Á¦ÇÑÇÕ´Ï´Ù. ÀÌ·¯ÇÑ ¿äÀÎÀ¸·Î ÀÎÇØ °ú¹Î¼º´ëÀåÁõÈıº Ä¡·áÀÇ Çʿ伺ÀÌ ´õ¿í ³ô¾ÆÁ® ȯÀÚ°¡ ±ÔÄ¢ÀûÀÎ »ýȰÀ» ÇÒ ¼ö ÀÖ½À´Ï´Ù.

IBS ȯÀÚÀÇ ¾à 40%´Â °æÁõ, 35%´Â Áߵ IBS, 25%´Â ÁßÁõ IBSÀ̸ç, IBS Áõ»óÀ» ±¸ºÐÇÏÁö ¸øÇÏ´Â »ç¶÷ÀÌ »ó´çÈ÷ ¸¹±â ¶§¹®¿¡ IBS´Â ¿©ÀüÈ÷ Àǻ簡 Áø´ÜÇÏ´Â °¡Àå ÈçÇÑ Áúȯ Áß ÇϳªÀ̸ç, IBS Áõ»óÀÌ ÀÖ´Â ¸ðµç »ç¶÷ÀÌ Ä¡·á¸¦ ¹Þ´Â °ÍÀº ¾Æ´Õ´Ï´Ù. ÇÏÁö¸¸ ¹Ì±¹¿¡¼­¸¸ ¿¬°£ 240¸¸-350¸¸ ¸íÀÌ °ú¹Î¼º´ëÀåÁõÈıºÀ¸·Î º´¿øÀ» ã½À´Ï´Ù. Àü ¼¼°èÀûÀ¸·Î ³²¼ºÀÇ ¾à 35-40%, ¿©¼ºÀÇ ¾à 60-65%°¡ °ú¹Î¼º´ëÀåÁõÈıºÀ» ¾Î°í ÀÖ½À´Ï´Ù.

°ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå º¸°í¼­ ÇÏÀ̶óÀÌÆ®

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý°ú ¹üÀ§

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå °ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå º¯¼ö, µ¿Çâ, ¹üÀ§

Á¦4Àå °ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå : À¯Çü ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦5Àå °ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå : ¾à¹° Á¾·ù ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦6Àå °ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå : À¯Åë ä³Î ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦7Àå °ú¹Î¼º´ëÀåÁõÈıº Ä¡·á ½ÃÀå : Áö¿ª ÃßÁ¤¡¤µ¿Ç⠺м®

Á¦8Àå °æÀï »óȲ

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Irritable Bowel Syndrome Treatment Market Growth & Trends:

The global irritable bowel syndrome treatment market size is expected to reach USD 6.02 billion by 2030, registering a CAGR of 8.8% from 2025 to 2030, according to a new report by Grand View Research, Inc. Rising prevalence of target disease and increasing label extension of existing drugs are likely to accelerate market growth. In addition, growing uptake of drugs and launch of novel products are anticipated to drive the irritable bowel syndrome (IBS) treatment market.

IBS is one of the most common gastrointestinal disorders, with the worldwide prevalence rate usually ranging between 10-15%. Most of the patients with IBS are under 50 years of age but many older adults suffer as well. The effect of the condition can vary from mild inconvenience to serious debilitation. It can control many facets of a patient's professional, emotional, and social life. Patients with moderate to severe conditions usually struggle with symptoms that frequently impair their emotional, physical, educational, social, and economic wellbeing.

Symptoms can vary and are sometimes contradictory, constipation can alternate with diarrhea. Long-term symptoms can disturb the patient's professional and personal activities, and usually limits an individual's potential.These factors further increase the need for irritable bowel syndrome treatment, which enable patients to go on with their regular life.

Around 40% patients have mild IBS, 35% have moderate IBS, and 25% have severe IBS. A significant number of people cannot distinguish IBS symptoms; it is still one of the most common disorders diagnosed by physicians. Not everyone with IBS symptoms pursues treatment for the same. Though, there are around 2.4-3.5 million yearly doctor visits for irritable bowel syndrome in U.S. alone. Globally, it affects around 35-40% of males and 60-65% of females.

Irritable Bowel Syndrome Treatment Market Report Highlights:

Table of Contents

Chapter 1. Methodology and Scope

Chapter 2. Executive Summary

Chapter 3. Irritable Bowel Syndrome Treatment Market Variables, Trends, & Scope

Chapter 4. Irritable Bowel Syndrome Treatment Market: Type Estimates & Trend Analysis

Chapter 5. Irritable Bowel Syndrome Treatment Market: Drug Class Estimates & Trend Analysis

Chapter 6. Irritable Bowel Syndrome Treatment Market: Distribution Channel Estimates & Trend Analysis

Chapter 7. Irritable Bowel Syndrome Treatment Market: Regional Estimates & Trend Analysis

Chapter 8. Competitive Landscape

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â